Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

FHTX

Foghorn Therapeutics Inc

Dec 10 • 04:00PM ET

6.26

Dollar change -0.04
Percentage change -0.63	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP SRPT BLUE BEAM EDIT NTLA QURE VYGR ABEO PASG

| Held by: VTI IWM VXF IWO VTWO IWN IWC CNCR VTWG RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.91	Insider Own	49.79%	Shs Outstand	55.59M	Perf Week	-17.85%
Market Cap	348.01M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	-0.28%	Shs Float	27.91M	Perf Month	-33.05%
Income	-91.22M	PEG	-	EPS next Q	-0.35	Inst Own	41.60%	Short Float	3.52%	Perf Quarter	-32.47%
Sales	25.52M	P/S	13.64	EPS this Y	30.22%	Inst Trans	2.71%	Short Ratio	6.27	Perf Half Y	5.03%
Book/sh	-0.51	P/B	-	EPS next Y	10.50%	ROA	-29.34%	Short Interest	0.98M	Perf Year	11.19%
Cash/sh	4.81	P/C	1.30	EPS next 5Y	-	ROE	-	52W Range	2.70 - 10.25	Perf YTD	-2.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-26.80%	ROI	-4531.69%	52W High	-38.93%	Beta	3.12
Dividend TTM	-	Quick Ratio	4.77	Sales past 5Y	328.43%	Gross Margin	87.51%	52W Low	131.85%	ATR (14)	0.57
Dividend Ex-Date	-	Current Ratio	4.77	EPS Y/Y TTM	22.53%	Oper. Margin	-398.74%	RSI (14)	29.33	Volatility	9.25% 7.88%
Employees	116	Debt/Eq	-	Sales Y/Y TTM	-21.66%	Profit Margin	-357.53%	Recom	1.29	Target Price	16.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	10.52%	Payout	-	Rel Volume	0.65	Prev Close	6.30
Sales Surprise	23.05%	EPS Surprise	27.91%	Sales Q/Q	-55.33%	Earnings	Nov 04 AMC	Avg Volume	156.75K	Price	6.26
SMA20	-18.35%	SMA50	-20.50%	SMA200	-9.60%	Trades		Volume	102,547	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-24	Initiated	Jefferies	Buy	$18
Aug-19-24	Initiated	Evercore ISI	Outperform	$20
Mar-28-23	Initiated	BofA Securities	Buy	$10
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$20
Nov-22-21	Initiated	H.C. Wainwright	Buy	$25
Nov-17-20	Initiated	Wedbush	Outperform	$24
Nov-17-20	Initiated	Morgan Stanley	Overweight	$24
Nov-17-20	Initiated	Goldman	Buy	$27
Nov-17-20	Initiated	Cowen	Outperform

Nov-29-24 12:00PM	Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why (Zacks)
Nov-25-24 09:55AM	Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? (Zacks)
Nov-20-24 08:00AM	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies (PR Newswire)
06:30AM	Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer (PR Newswire)
Nov-13-24 08:00AM	Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio (PR Newswire)
08:00AM	Loading…
08:00AM	Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner (PR Newswire)
Nov-12-24 07:54AM	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 05:25PM	Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +8.50%
04:05PM	Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update (GlobeNewswire)
Oct-23-24 08:00AM	Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence (PR Newswire)
Oct-11-24 07:47AM	Foghorn Therapeutics Unveils Clinical Pipeline Progress (TipRanks) +8.07%
Oct-10-24 07:00AM	Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors (GlobeNewswire)
Oct-09-24 07:00AM	Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions (PR Newswire)
Oct-03-24 08:00AM	Invaio Sciences Appoints Andr Andonian as Chairman of the Board of Directors (PR Newswire) -10.20%
Oct-01-24 07:00AM	Foghorn Therapeutics to Participate in the BMO Oncology Summit (GlobeNewswire) -6.87%
06:00AM	Loading…
Sep-26-24 06:00AM	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry (PR Newswire) +5.79%
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-16-24 04:12AM	Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? (Zacks)
Sep-11-24 07:02PM	Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ... (GuruFocus.com)
Sep-03-24 07:00AM	Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer (GlobeNewswire) -5.19%
Sep-02-24 09:55AM	Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet (Zacks)
Aug-28-24 07:00AM	Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
06:30AM	Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer (PR Newswire)
Aug-16-24 09:55AM	Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade (Zacks)
Aug-08-24 08:10AM	Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update (GlobeNewswire)
Aug-06-24 06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Jul-29-24 07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)
Jul-23-24 06:00AM	Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class (PR Newswire) +5.09%
08:00AM	Loading…
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jul-10-24 06:00AM	Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability (PR Newswire)
06:00AM	Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions (PR Newswire)
Jun-12-24 07:00AM	Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer (PR Newswire)
May-28-24 07:00AM	Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-22-24 06:21PM	Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline (GlobeNewswire)
May-20-24 11:14AM	Foghorn Therapeutics Prices $110 Million Offering of Shares, Pre-Funded Warrants (MT Newswires) +8.89%
07:58AM	Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-09-24 07:00AM	Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration with Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management (PR Newswire)
May-06-24 02:52PM	FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:32AM	Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ... (GuruFocus.com)
08:10AM	Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update (GlobeNewswire)
Apr-16-24 07:00AM	Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer (GlobeNewswire) -5.63%
Apr-09-24 04:30PM	Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs (GlobeNewswire)
Apr-08-24 08:00AM	Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences (PR Newswire)
Apr-05-24 07:00AM	Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 09:55AM	Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect? (Zacks)
Mar-26-24 07:00AM	Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting (GlobeNewswire)
Mar-19-24 08:30AM	Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (PR Newswire)
Mar-13-24 12:00PM	Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know (Zacks)
Mar-07-24 02:52PM	FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:20AM	Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook (GlobeNewswire)
Mar-05-24 04:48PM	Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 (GlobeNewswire) -5.89% +6.26%
Feb-28-24 07:00AM	Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference (GlobeNewswire) +8.06%
Feb-12-24 02:43AM	Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last? (Zacks)
Feb-09-24 10:02AM	Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development (Zacks) +22.68%
Feb-08-24 07:00AM	Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor (GlobeNewswire) +55.45%
Jan-09-24 08:44AM	DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING (PR Newswire) -9.17%
Jan-08-24 07:00AM	Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 (GlobeNewswire) +6.38%
06:30AM	Flagship Pioneering Debuts Enabling Technologies Initiative (PR Newswire)
06:30AM	Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine (PR Newswire)
Jan-03-24 04:05PM	Foghorn Therapeutics Announces CFO Departure (GlobeNewswire) -6.82% -6.82%
Dec-26-23 12:00PM	Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why (Zacks)
Dec-11-23 09:55AM	How Much Upside is Left in Foghorn Therapeutics Inc. (FHTX)? Wall Street Analysts Think 160.57% (Zacks) -12.79%
Dec-01-23 07:00AM	Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting (GlobeNewswire) +5.65%
Nov-27-23 07:01PM	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders (PR Newswire)
Nov-21-23 06:00AM	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics (PR Newswire)
Nov-03-23 06:12AM	Foghorn Therapeutics Inc (FHTX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
Nov-02-23 07:00AM	Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update (GlobeNewswire) +7.07%
Nov-01-23 10:30AM	Flagship Pioneering Launches Pioneering Intelligence (PR Newswire) +9.85%
Oct-24-23 08:00AM	Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs (GlobeNewswire)
Oct-19-23 10:30AM	Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines (PR Newswire) -6.26%
Oct-13-23 08:00AM	Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress (GlobeNewswire)
Oct-04-23 08:00AM	Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-02-23 07:00AM	Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics (PR Newswire) -11.20%
Sep-27-23 08:31AM	Flagship Pioneering Named to Fortune's 2023 'Change the World' List (PR Newswire) +7.35%
Sep-11-23 06:30AM	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer (PR Newswire)
Sep-05-23 08:00AM	Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-31-23 07:00AM	Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML (GlobeNewswire)
Aug-29-23 09:00AM	Invaio achieves first registration for citrus greening solution featuring Trecise technology (PR Newswire)
Aug-11-23 03:54PM	These Analysts Think Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Sales Are Under Threat (Simply Wall St.)
Aug-08-23 07:00AM	Foghorn Therapeutics Announces Chief Medical Officer Succession (GlobeNewswire)
Aug-04-23 08:15AM	Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update (GlobeNewswire)
Jul-09-23 07:58PM	Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains? (Zacks)
Jun-28-23 01:44PM	Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer (Benzinga)
07:00AM	Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma (GlobeNewswire)
Jun-07-23 08:00AM	Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +6.75%
Jun-06-23 07:56AM	Investors in Foghorn Therapeutics (NASDAQ:FHTX) from a year ago are still down 47%, even after 20% gain this past week (Simply Wall St.)
Jun-05-23 07:00AM	Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients (GlobeNewswire)
May-16-23 06:00AM	Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry (PR Newswire)
May-10-23 07:47AM	We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely (Simply Wall St.) +14.71%
May-08-23 08:15AM	Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -10.25%
07:00AM	Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update (GlobeNewswire)
Apr-27-23 04:35AM	Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? (Zacks)
Apr-25-23 04:05PM	Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -5.01% +13.10%
Apr-24-23 01:28PM	More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold (Benzinga) -7.89%

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Costa Carlos	Chief People Officer	Sep 20 '24	Option Exercise	3.72	35,756	133,012	35,756	Sep 24 04:01 PM
Costa Carlos	Chief People Officer	Sep 23 '24	Option Exercise	3.72	857	3,188	857	Sep 24 04:01 PM
Costa Carlos	Chief People Officer	Sep 20 '24	Sale	10.04	35,756	358,990	0	Sep 24 04:01 PM
Costa Carlos	Chief People Officer	Sep 23 '24	Sale	10.17	857	8,716	0	Sep 24 04:01 PM
Costa Carlos	Chief People Officer	Sep 18 '24	Option Exercise	3.72	11,574	43,055	11,574	Sep 20 04:00 PM
Costa Carlos	Chief People Officer	Sep 18 '24	Sale	10.05	11,574	116,319	0	Sep 20 04:00 PM
Costa Carlos	Chief People Officer	Sep 17 '24	Option Exercise	3.72	10,272	38,212	10,272	Sep 18 04:01 PM
Costa Carlos	Chief People Officer	Sep 16 '24	Option Exercise	3.72	400	1,488	400	Sep 18 04:01 PM
Costa Carlos	Chief People Officer	Sep 17 '24	Sale	10.04	10,272	103,131	0	Sep 18 04:01 PM
Costa Carlos	Chief People Officer	Sep 16 '24	Sale	10.00	400	4,000	0	Sep 18 04:01 PM
CARLOS COSTA	Officer	Sep 16 '24	Proposed Sale	9.72	98,648	958,859		Sep 16 04:40 PM
Bellon Steven F.	Chief Scientific Officer	Sep 09 '24	Sale	9.50	20,000	190,000	101,957	Sep 11 04:00 PM
STEVEN BELLON	Officer	Sep 09 '24	Proposed Sale	7.53	20,000	150,600		Sep 09 04:31 PM
Cavalie Fanny	Chief Strategy/Bus Ops Officer	Mar 11 '24	Sale	6.56	11,000	72,134	75,992	Mar 12 04:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FHTX

Foghorn Therapeutics Inc

Upgrade your FINVIZ experience